A Whole Blood Assay to assess Individual Patient Responses to Novel Antiviral Therapeutics.
While combination anti-retroviral drugs (cART) can control active HIV-1 virus replication, they are not “curative”. Rather, these drugs are required life-long. Developing new therapeutic strategies that can reduce or clear persistent, underlying sources of virus infection will require novel clinical diagnostic assays and tools. Such tools must comprehensively evaluate virologic, immunologic and safety parameters for individuals who may require personalized therapies.
Jericho Sciences is developing a clinically relevant, diagnostic assay for personalized clinical management of novel therapeutic strategies for controlling HIV-1 infection. Our patented technology assesses patient-specific responses across comparative conditions using multiparametric measures from the full peripheral blood immunologic compartment. Other assays exclude cells other than CD4+ T cells. Jericho’s assay more accurately reflects the natural environment of CD4+ T cells, the primary targets of HIV infection.
How the J-Test® Works
- Draw blood into prefilled collection tubes
- Incubate up to 72 hours
- Separate supernatant and cells
- Perform analyses
- Select responders and/or therapeutics
A successful therapeutic approach will likely require
- selection of clinically safe and effective combinations of therapeutics;
- patient-specific preclinical testing;
- immune-boosting agents; and
- biomarkers to delineate patient selection criteria and to monitor longitudinal responses.
Current latency assays fail to provide the capacity to deliver this breadth of outputs.
Jericho’s J-Test® Value Proposition
- Clinically Relevant: Requires small volumes of fresh blood
- Patient-Specific: Internally-referenced
- Short Turnaround Time: Results within 1 week
- Multiparametric: Cellular, viral, and immunologic parameters
- Primary Cells: Immediate responses to virus activation
- Supports Clinical Success: Enables identification of biomarkers
A key remaining question is whether virus-specific immune mechanisms including cytolytic T lymphocytes (CTL) can clear infected cells in ART-treated patients after latency is reversed. […] appropriate boosting of this response may be required for the elimination of the latent reservoir.”-K Deng et al., (2015) Nature 517,7534: 381-5.
to inquire how the J-Test® can better support clinical success of novel antiviral therapeutics
…the heterogeneity of the reservoirs and the multiplicity of the mechanisms which underlie latency and probably vary from one patient to the other and even from one cell to the other in single patient. This observation […] emphasizes the need to evaluate the efficacy of an LRA [latency reversing agent] first ex vivo in cell cultures from a given patient before the administration of this LRA to this given patient in vivo in the context of a clinical trial.”-G Darcis et al., (2015) PLoS Pathog 11(7);